Search results
Results from the WOW.Com Content Network
Iodine-131 (131 I, I-131) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. [3] It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production.
Iodine-124 can be made by numerous nuclear reactions via a cyclotron. The most common starting material used is 124 Te. Iodine-124 as the iodide salt can be used to directly image the thyroid using positron emission tomography (PET). [9] Iodine-124 can also be used as a PET radiotracer with a usefully longer half-life compared with fluorine-18 ...
The test was first introduced in 1956, using iodine-131 diodrast. [25] [26] Later developments included iodine-131, and then iodine-123, labelled ortho-Iodohippuric acid (OIH, marketed as Hippuran). [27] [28] 99m Tc-MAG3 has replaced 131 I-OIH because of better quality imaging regardless of the level of kidney function, [29] and lower radiation ...
The non-radioactive iodide "saturates" the thyroid, causing less of the radioiodine to be stored in the body. Administering potassium iodide reduces the effects of radio-iodine by 99% and is a prudent, inexpensive supplement to fallout shelters. A low-cost alternative to commercially available iodine pills is a saturated solution of potassium ...
The high short-term radioactivity of spent nuclear fuel is primarily from fission products with short half-life.The radioactivity in the fission product mixture is mostly due to short-lived isotopes such as 131 I and 140 Ba, after about four months 141 Ce, 95 Zr/ 95 Nb and 89 Sr constitute the largest contributors, while after about two or three years the largest share is taken by 144 Ce/ 144 ...
Iodine-123 (123 I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2232 hours; [1] the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV (this is the gamma primarily used for imaging).
Often called the father of nuclear medicine, Lawrence treated a leukemia patient with radiophosphorus, which was the first time a radioactive isotope has been used to treat human patients. [4] Another pioneer in the field, Sam Seidlin, in partnership with Saul Hertz, treated a case of thyroid cancer with radioactive iodine (I-131) 1946. [5]
Iodine-129 (129 I) is a long-lived radioisotope of iodine that occurs naturally but is also of special interest in the monitoring and effects of man-made nuclear fission products, where it serves as both a tracer and a potential radiological contaminant.